凝集素樣氧化低密度脂蛋白受體1(LOX1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Lectin Like Oxidized Low Density Lipoprotein Receptor 1 (LOX1)
OLR1; CLEC8A; SCARE1; Oxidized low-density lipoprotein receptor 1; C-type lectin domain family 8 member A; Lectin-like oxidized LDL receptor 1; Lectin-type oxidized LDL receptor 1
- 編號(hào)USEB859Hu
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)3h
- 檢測(cè)范圍0.156-10ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.060ng/mL.
- 樣本類型serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說(shuō)明書 中文說(shuō)明書
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價(jià)格 ¥ 1397 ¥ 1995 ¥ 8978 ¥ 16958 ¥ 139650
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
實(shí)驗(yàn)結(jié)果圖
-
標(biāo)準(zhǔn)曲線圖
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)凝集素樣氧化低密度脂蛋白受體1(LOX1)，經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的凝集素樣氧化低密度脂蛋白受體1(LOX1)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 97-105 | 102 |
| EDTA plasma(n=5) | 88-97 | 92 |
| heparin plasma(n=5) | 78-99 | 94 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的凝集素樣氧化低密度脂蛋白受體1(LOX1)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中凝集素樣氧化低密度脂蛋白受體1(LOX1)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 83-103% | 92-99% | 91-98% | 96-105% |
| EDTA plasma(n=5) | 84-92% | 95-104% | 89-101% | 79-97% |
| heparin plasma(n=5) | 99-105% | 86-101% | 87-103% | 80-91% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）100µL，37°C孵育1小時(shí)；
3. 吸棄，加檢測(cè)溶液A100µL，37°C孵育1小時(shí)；
4. 洗板3次；
5. 加檢測(cè)溶液B100µL，37°C孵育30分鐘；
6. 洗板5次；
7. 加TMB底物90µL，37°C孵育10-20分鐘；
8. 加終止液50µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
將凝集素樣氧化低密度脂蛋白受體1(LOX1)抗體包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的凝集素樣氧化低密度脂蛋白受體1(LOX1)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的凝集素樣氧化低密度脂蛋白受體1(LOX1)抗體，將未結(jié)合的生物素化抗體洗凈后，加入HRP標(biāo)記的親和素，再次徹底洗滌后加入TMB底物顯色。TMB在過(guò)氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的凝集素樣氧化低密度脂蛋白受體1(LOX1)呈正相關(guān)。用酶標(biāo)儀在450nm波長(zhǎng)下測(cè)定吸光度(O.D.值)，計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| URPB859Hu01 | 凝集素樣氧化低密度脂蛋白受體1(LOX1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAB859Hu01 | 凝集素樣氧化低密度脂蛋白受體1(LOX1)多克隆抗體 | WB; IHC; ICC/IF |
| UMAB859Hu23 | 凝集素樣氧化低密度脂蛋白受體1(LOX1)單克隆抗體 | ICC/IF |
| UMAB859Hu21 | 凝集素樣氧化低密度脂蛋白受體1(LOX1)單克隆抗體 | WB; ICC/IF |
| UMAB859Hu22 | 凝集素樣氧化低密度脂蛋白受體1(LOX1)單克隆抗體 | ICC/IF |
| UMAB859Hu24 | 凝集素樣氧化低密度脂蛋白受體1(LOX1)單克隆抗體 | WB; ICC/IF |
| USEB859Hu | 凝集素樣氧化低密度脂蛋白受體1(LOX1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| ULMB859Hu | 凝集素樣氧化低密度脂蛋白受體1(LOX1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| UKSB859Hu01 | 凝集素樣氧化低密度脂蛋白受體1(LOX1)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Clinical Cardiology | Circulating Soluble Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Levels Are Associated With Angiographic Coronary Lesion Complexity in Patients With Coronary Artery Diseas [PubMed: 21400544] |
| Coronary Artery Disease | Postprocedural serum sLOX-1 levels are associated with coronary in-stent restenosis in patients with stable coronary artery disease [LWW: 06000] |
| Clinical Biochemistry | Soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in synovial fluid are correlated with disease severity of knee osteoarthritis [ScienceDirect: S0009912011004905] |
| Mediators of Inflammation | Pregnancy Followed by Delivery May Affect Circulating Soluble Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Levels in Women of Reproductive Age [PubMed: 22619487] |
| Dicle Medical Journal | Lectin-like oxidized low density lipoprotein receptor 1(LOX-1) levels and endothelial dysfunction in patients with primary essential hyperhidrosis/Primer esansiyel hiperhidroz hastalarinda lektin benzeri okside düsük dansiteli lipoprotein reseptor 1(LOX-1) düzeyleri ve endotel disfonksiyonu [Readperiodicals: Source] |
| Journal of Clinical Laboratory Analysis | Soluble Lectin-Like Oxidized LDL Receptor 1 as a Possible Mediator of Endothelial Dysfunction in Patients With Metabolic Syndrome [Pubmed:24798146] |
| Journal of Human Hypertension | Endothelial damage in white coat hypertension: role of lectin-like oxidized low-density lipoprotein-1 [Pubmed:25007999] |
| Gynecologic and Obstetric Investigation | Inhibition of Lectin-Like Oxidized Low-Density Lipoprotein Receptor 1 Protects against Plasma/Hypoxia-Mediated Trophoblast Dysfunction Associated with Preeclampsia [Pubmed:25633310] |
| World J Gastroenterol | Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease [PubMed: 26185381] |
| Genetic Testing and Molecular Biomarkers | Serum sLOX-1 Levels Are Correlated with the Presence and Severity of Obstructive Sleep Apnea [PubMed: 25825846] |
| Neurotoxicology. | 27-Hydroxycholesterol regulates cholesterol synthesis and transport in C6 glioma cells. [pubmed:28167099] |
| Journal of the American?Heart?Association | Increased Levels of Lectin‐Like Oxidized Low‐Density Lipoprotein Receptor‐1 in Ischemic Stroke and Transient Ischemic Attack [Pubmed:29330254] |
| Higher serum lectin-like oxidized low-density lipoprotein receptor-1 in patients with stable coronary artery disease is associated with major adverse?… [] | |
| Disease Markers | Baseline Serum sLOX-1 Concentrations Are Associated with 2-Year Major Adverse Cardiovascular and Cerebrovascular Events in Patients after Percutaneous?… [Pubmed: 31772687] |
| Reproductive Biology | Polycystic ovary syndrome and endothelial dysfunction: A potential role for soluble lectin-like oxidized low density lipoprotein receptor-1 [Pubmed: 32409108] |
| Int J Cancer | The oxidized‐LDL/LOX‐1 axis in tumor endothelial cells enhances metastasis by recruiting neutrophils and cancer cells [Pubmed:35608341] |
